UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Gastroenterology (New York, N.Y. 1943), 2015, Vol.148 (1), p.221-244.e3

2015

Volltextzugriff (PDF)

Hepatitis B virus reactivation during direct‐acting antiviral treatment of chronic hepatitis C: A hidden danger of an otherwise major success story

Hepatology (Baltimore, Md.), 2017-07, Vol.66 (1), p.4-6

Perrillo, Robert P.

2017

Volltextzugriff (PDF)

Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy

Clinical infectious diseases, 2016-06, Vol.62 (suppl 4), p.S306-S313

2016

Volltextzugriff (PDF)

Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease

Gastroenterology (New York, N.Y. 1943), 2001-03, Vol.120 (4), p.1009-1022

Perrillo, Robert P.

2001

Volltextzugriff (PDF)

Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States

The New England journal of medicine, 1999-10, Vol.341 (17), p.1256-1263

1999

Volltextzugriff (PDF)

Current Treatment of Chronic Hepatitis B: Benefits and Limitations

Seminars in liver disease, 2005-01, Vol.25 (S 1), p.20-28

Perrillo, Robert P

2005

Volltextzugriff (PDF)

Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis B

Hepatology (Baltimore, Md.), 2024-06, Vol.79 (6), p.E159-E159

2024

Volltextzugriff (PDF)

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg?

Hepatology (Baltimore, Md.), 2015-02, Vol.61 (2), p.703-711

2015

Volltextzugriff (PDF)

Preventing hepatitis B reactivation due to immunosuppressive drug treatments

JAMA : the journal of the American Medical Association, 2015-04, Vol.313 (16), p.1617

2015

Volltextzugriff (PDF)

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B

Hepatology (Baltimore, Md.), 2002-07, Vol.36 (1), p.186-194

2002

Volltextzugriff (PDF)

A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection

The New England journal of medicine, 1995-12, Vol.333 (25), p.1657-1661

1995

Volltextzugriff (PDF)

Tumor necrosis factor inhibitor therapy for hepatitis B virus–infected individuals: How loud is the alarm bell?

Hepatology (Baltimore, Md.), 2015-07, Vol.62 (1), p.16-18

Perrillo, Robert P.

2015

Volltextzugriff (PDF)

Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial

The American journal of gastroenterology, 2023-07, Vol.118 (7), p.1226-1236

2023

Volltextzugriff (PDF)

Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN trials

Hepatology (Baltimore, Md.), 2024-04

2024

Volltextzugriff (PDF)

An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus

Journal of clinical gastroenterology, 2022-07, Vol.56 (6), p.478-492

2022

Volltextzugriff (PDF)

Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection

Clinical gastroenterology and hepatology, 2023-06, Vol.21 (6), p.1503-1512.e4

2023

Volltextzugriff (PDF)

Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B

The American journal of gastroenterology, 2023-07, Vol.118 (7), p.1214-1225

2023

Volltextzugriff (PDF)

Therapy of hepatitis B — Viral suppression or eradication?

Hepatology (Baltimore, Md.), 2006-02, Vol.43 (S1), p.S182-S193

Perrillo, Robert P.

2006

Volltextzugriff (PDF)

Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?

Hepatology (Baltimore, Md.), 2002-07, Vol.36 (1), p.150-155

2002

Volltextzugriff (PDF)

A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B

Hepatology (Baltimore, Md.), 2001-02, Vol.33 (2), p.424-432

2001

Volltextzugriff (PDF)

Hepatitis B surface antigen quantification as a current‐day paradox: Obtaining the gold in the face of diminishing returns

Hepatology (Baltimore, Md.), 2009-04, Vol.49 (4), p.1063-1065

Perrillo, Robert P.

2009

Volltextzugriff (PDF)

Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis

The New England journal of medicine, 1992-12, Vol.327 (27), p.1906-1911

1992

Volltextzugriff (PDF)

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B

Journal of hepatology, 2008-05, Vol.48 (5), p.728-735

2008

Volltextzugriff (PDF)

Hepatitis B virus genotypes in the United States: results of a nationwide study

Gastroenterology (New York, N.Y. 1943), 2003-08, Vol.125 (2), p.444-451

2003

Volltextzugriff (PDF)

Hepatitis B reactivation from immunosuppressive drug therapy: A global menace: Editor's comment for february issue of clinical liver disease

Clinical liver disease (Malden, Mass.), 2015-02, Vol.5 (2), p.39

Perrillo, Robert P

2015

Volltextzugriff (PDF)

1 – 25 von 172

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Englisch
(169)
Japanisch
(26)
Deutsch
(2)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Hepatitis B virus reactivation during direct‐acting antiviral treatment of chronic hepatitis C: A hidden danger of an otherwise major success story

Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy

Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease

Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States

Current Treatment of Chronic Hepatitis B: Benefits and Limitations

Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis B

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg?

Preventing hepatitis B reactivation due to immunosuppressive drug treatments

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B

A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection

Tumor necrosis factor inhibitor therapy for hepatitis B virus–infected individuals: How loud is the alarm bell?

Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial

Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN trials

An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus

Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection

Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B

Therapy of hepatitis B — Viral suppression or eradication?

Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?

A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B

Hepatitis B surface antigen quantification as a current‐day paradox: Obtaining the gold in the face of diminishing returns

Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B

Hepatitis B virus genotypes in the United States: results of a nationwide study

Hepatitis B reactivation from immunosuppressive drug therapy: A global menace: Editor's comment for february issue of clinical liver disease

Suchergebnisse filtern